Lumexa Imaging (NASDAQ:LMRI) Stock Gets Price Target Boost from Wells Fargo & Company

Lumexa Imaging logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wells Fargo raised Lumexa Imaging’s price target to $21 from $19 and maintained an Overweight rating, implying 45.21% upside from the stock’s $14.46 price at the time of the report.
  • Analyst sentiment is generally positive: MarketBeat reports a consensus Buy rating and an average price target of $18.17, with two Strong Buy, four Buy, and one Sell rating.
  • Lumexa reported quarterly EPS of $0.26, beating the $0.07 consensus estimate by $0.19; quarterly revenue was $271.97 million.
  • Five stocks we like better than Lumexa Imaging.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) had its price target upped by equities research analysts at Wells Fargo & Company from $19.00 to $21.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Wells Fargo & Company's price objective indicates a potential upside of 45.21% from the stock's current price.

Other equities research analysts also recently issued reports about the stock. Deutsche Bank set a $16.00 price objective on shares of Lumexa Imaging in a research note on Thursday, August 13th. KeyCorp assumed coverage on shares of Lumexa Imaging in a research note on Thursday, September 24th. They issued an "overweight" rating and a $18.00 target price for the company. Wall Street Zen upgraded shares of Lumexa Imaging from a "hold" rating to a "buy" rating in a research report on Saturday, October 3rd. Raymond James Financial set a $19.00 price objective on Lumexa Imaging and gave the company a "strong-buy" rating in a report on Wednesday, November 11th. Finally, Barclays upped their price objective on shares of Lumexa Imaging from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $18.17.

View Our Latest Stock Report on LMRI

Lumexa Imaging Stock Performance

LMRI traded down $0.17 on Wednesday, hitting $14.46. The company's stock had a trading volume of 11,307 shares, compared to its average volume of 670,365. The company's 50 day simple moving average is $11.57 and its 200-day simple moving average is $11.10. The firm has a market cap of $1.39 billion and a P/E ratio of -26.81. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.36. Lumexa Imaging has a 12 month low of $6.45 and a 12 month high of $19.45.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.07 by $0.19. The business had revenue of $271.97 million for the quarter. Lumexa Imaging had a negative net margin of 1.96% and a negative return on equity of 2.89%. Analysts forecast that Lumexa Imaging will post 0.27 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Aquatic Capital Management LLC purchased a new stake in Lumexa Imaging during the 3rd quarter worth about $77,000. Beck Mack & Oliver LLC raised its stake in Lumexa Imaging by 61.1% in the 3rd quarter. Beck Mack & Oliver LLC now owns 275,075 shares of the company's stock valued at $2,820,000 after purchasing an additional 104,375 shares during the last quarter. Pathstone Holdings LLC purchased a new stake in Lumexa Imaging in the 3rd quarter valued at about $193,000. First Eagle Investment Management LLC purchased a new stake in Lumexa Imaging during the third quarter valued at about $4,753,000. Finally, Royce & Associates LP boosted its position in Lumexa Imaging by 25.3% during the 3rd quarter. Royce & Associates LP now owns 988,517 shares of the company's stock worth $10,132,000 after purchasing an additional 199,477 shares during the period.

Lumexa Imaging Company Profile

(Get Free Report)

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.

Featured Articles

Analyst Recommendations for Lumexa Imaging (NASDAQ:LMRI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lumexa Imaging Right Now?

Before you consider Lumexa Imaging, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lumexa Imaging wasn't on the list.

While Lumexa Imaging currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines